首页> 外文期刊>American Journal of Kidney Diseases: The official journal of the National Kidney Foundation >Comparative Effectiveness of Medical Therapy, Percutaneous Revascularization, and Surgical Coronary Revascularization in Cardiovascular Risk Subgroups of Patients With CKD: A Retrospective Cohort Study of Medicare Beneficiaries
【24h】

Comparative Effectiveness of Medical Therapy, Percutaneous Revascularization, and Surgical Coronary Revascularization in Cardiovascular Risk Subgroups of Patients With CKD: A Retrospective Cohort Study of Medicare Beneficiaries

机译:CKD患者心血管风险亚组中医学治疗,经皮血运重建和外科冠状动脉血运重建的比较效果:医疗保险受益者的回顾性队列研究

获取原文
获取原文并翻译 | 示例
           

摘要

Rationale & Objective: Prior studies suggesting that medical therapy is inferior to percutaneous (percutaneous coronary intervention [PCI]) or surgical (coronary artery bypass grafting [CABG]) coronary revascularization in chronic kidney disease (CKD) have not adequately considered medication optimization or baseline cardiovascular risk and have infrequently evaluated progression to kidney failure. We compared, separately, the risks for kidney failure and death after treatment with PCI, CABG, or optimized medical therapy for coronary disease among patients with CKD stratified by cardiovascular disease risk.
机译:理由和目的:提前研究表明,医疗治疗不如经皮(经皮冠状动脉介入[PCI])或外科(冠状动脉旁路接枝[CABG])慢性肾病(CKD)的冠状动脉血运重建没有充分考虑药物优化或基线 心血管风险,并且对肾衰竭的进展不经常。 我们比较,单独进行肾功能衰竭和死亡后的风险,在用心血管疾病风险的CKD分层患者中治疗冠状动脉疾病的冠状动脉疾病后。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号